A single chain Fv specific against Western equine encephalitis virus

Hybridoma

Volumn 18, Issue 4, 1999, Pages 315-323

  Xu, Biwen ^a   Kriangkum, Jitra ^a   Nagata, Les P ^b   Fulton, R Elaine ^b   Suresh, Mavanur R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CFB Suffield   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; HYBRIDOMA; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; VIRUS ENCEPHALITIS; VIRUS ENVELOPE; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ALPHAVIRUS; EQUIDAE; RNA VIRUSES; WESTERN EQUINE ENCEPHALOMYELITIS VIRUS;

EID: 0032706361     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.315     Document Type: Article

References (26)

1. Johnston RE, and Peters CJ: Alphaviruses. In: Field Virology, 3rd ed. Field BN, Knipe DM, Howley PM, et al. (Eds.). Lippincott-Raven Publishers, Philadelphia, 1996, pp. 843-898.
2. Calisher CH: Medically important arboviruses of the United States and Canada. Clin Microbiol Rev 1994;7:89-116.
3. Griffin D, Levine B, Tyor W, Ubol S, and Despres P: The role of antibody in recovery of alphavirus encephalitis. Immunol Rev 1997;159:155-161.
4. Matthews JH, and Roehrig JT: Determination of the protective epitopes in the glycoproteins of Venezuelan equine encephalitis virus by passive transfer of monoclonal antibodies. J Immunol 1982;129:2763-2767.
5. Boere WAM, Benaisssa-Trou WBJ, Harmsen M, Kraaijeveld CA, and Snippe H: Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki forest virus can protect mice from lethal encephalitis. J Gen Virol 1983;64:1405-1408.
6. Coppenhaver DH, Singh IP, Sarzotti M, Levy HB, and Baron S: Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. Am J Trop Med Hyg 1995;52:34-40.
7. Mendoza QP, Stanley J, and Griffin DE: Monoclonal antibodies to the E1 and E2 glycoproteins of Sindbis virus: Definition of epitopes and efficiency of protection from fatal encephalitis. J Gen Virol 1988;69:3015-3022.
8. Stanley J, Cooper SJ, and Griffin DE: Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J Virol 1986;58:107-115.
9. Schmaljohn AL, Johnson ED, Dalrymple JM, and Cole GA: Nonneutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 1982;297:70-72.
10. Roehrig JT, Day JW, and Kinney RM: Antigenic analysis of the surface of glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 1982; 118:269-278.
11. Kabat EA, Wu TT, Perry HM, Gottesman KS, and Foeller C: Sequences of proteins of immunological interest, 5th ed. Bethesda, MD, U.S. Department of Health and Human Services, Public Health Service, National Institute of Health, 1991.
12. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, and Pluckthun A: Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 1997;201:35-55.
13. Suresh MR, Noujaim AA, and Longenecker BM: Recent advances in monoclonal antibodies. In: Biotechnology: Current Progress, Cheremisinoff PN (eds.). New York, Technomic Publisher, 1991, pp. 83-101.
14. Yokota T, Milenic DE, Whitlow M, and Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.
15. Luo D, Mah N, Krantz M, Wilde K, Wishardt D, Jacobs F, and Martin L: Vl-linker-Vh orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the frame regions. J Biochem 1995;118:825-831.
16. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, and Weiner LM: Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998;58:485-490.
17. Dougan DA, Malby RL, Gruen LC, Kortt AA, and Hudson PJ: Effects of substitutions in the binding surface of an antibody on antigen affinity. Protein Eng 1998;11:65-74.
18. Kipriyaanov SM, Moldenhauer G, Martin ACR, Kupriyanova OA, and Little M: Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997;10:445-453.
19. Holliger P, and Winter G: Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother 1997;45:128-130.
20. Kortt AA, Lah M, Oddie GW, Gruen CL, Bums JE, Pearce LA, Atwell JJ, McCoy AJ, Howlett GJ, Metzger DW, et al.: Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five-and ten-residue linkers form dimers and with zero residue linker a trimer. Protein Eng 1997;10:423-433.
21. Pluckthun A, and Pack P: New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105.
22. Ubol S, Levine B, Lee S-H, Greenspan NS, and Griffin DE: Roles of immunoglobulin valency and the heavy chain constant domain in antibody-mediated downregulation of Sindbis virus replication in persistently infected neurons. J Virol 1995;69:1990-1993.
23. Cao Y, and Suresh MR: Bispecific antibodies as novel bioconjugates. Bioconjugate Chem 1998;9:635-644.
24. Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, Bagley J, Hinkula J, Niedrig M, Albert J, Wahren B, et al.: Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab introbodies against the matrix protein, p17. Mol Med 1997;3:96-110.
25. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Heiland DG, and Marasco WA: Inhibition of HIV-1 Tat-mediated LTR trans-activation and HIV-1 infection by anti-Tat single chain antibodies. EMBO J 1995;14:1542-1551.
26. Xu D. Bispecific antibody based ultrasensitive diagnostics. MSc. Thesis, University of Alberta, Edmonton, Canada.